Addition of the PCSK9 inhibitor evolocumab to statin therapy after cardiac bypass surgery did not improve 24-month graft patency in the NEWTON-CABG CardioLink-5 trial. Subodh Verma, MD, cardiac ...
MADRID — New data from two randomized trials suggest that dual antiplatelet therapy (DAPT) should be significantly shortened or not used at all after coronary artery bypass surgery (CABG). Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback